Key result
Cancer history linked to ~169% higher 1-year mortality following TEER.
Why the study?
Little was known regarding the prevalence of cancer history and its impact on clinical outcomes in patients with mitral regurgitation undergoing transcatheter mitral valve repair.
Does a history of cancer worsen all-cause mortality in patients undergoing transcatheter edge-to-edge mitral repair?
Cohort (n=446)
No
Does a history of cancer worsen all-cause mortality in patients undergoing transcatheter edge-to-edge mitral repair?
Hazard Ratio: 2.69 (95% CI 1.22–5.93)
Absolute Event Rate: 20.2% vs 9.2%
p-value: p=0.014
A history of cancer in patients undergoing transcatheter edge-to-edge mitral valve repair is associated with elevated baseline inflammatory markers and a significantly higher risk of 1-year all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Highlights elevated post-TEER mortality risk in cancer patients; hypothesis-generating and should not yet alter practice or selection criteria.
Tabata et al. (2020) conducted a cohort in Mitral regurgitation (n=446). History of cancer vs. No history of cancer was evaluated on All-cause mortality at 1 year (HR 2.69, 95% CI 1.22-5.93, p=0.014). In patients undergoing transcatheter edge-to-edge mitral repair, a history of cancer was associated with significantly higher 1-year all-cause mortality compared to non-cancer patients (20.2% vs 9.2%, HR 2.69).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: